Stock Locations

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

2088650-53-5Abemaciclib-D8

● In Stock

Catalogue No.:	DVE002129
CAS No.:	2088650-53-5
Mol. Formula:	C27H24D8F2N8
Mol. Weight:	514.65 g/mol

How can we help?

Add to RFQ list

Additional information on CAS 2088650-53-5

Parent drug

Abemaciclib

IUPAC Name

5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)-N-[5-[(2,2,3,3,5,5,6,6-octadeuterio-4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]pyrimidin-2-amine

Pharmacopeial Synonyms

N/A

Synonyms

N/A

Smiles

CC1=NC2=C(F)C=C(C3=NC(NC4=NC=C(CN5C([2H])([2H])C([2H])([2H])N(CC)C([2H])([2H])C5([2H])[2H])C=C4)=NC=C3F)C=C2N1C(C)C

InChI

InChI=1S/C27H32F2N8/c1-5-35-8-10-36(11-9-35)16-19-6-7-24(30-14-19)33-27-31-15-22(29)25(34-27)20-12-21(28)26-23(13-20)37(17(2)3)18(4)32-26/h6-7,12-15,17H,5,8-11,16H2,1-4H3,(H,30,31,33,34)/i8D2,9D2,10D2,11D2

Description

Abemaciclib-D8 (CAS 2088650-53-5) is an isotopically labeled impurity that requires targeted analytical control due to its deuterium incorporation and potential effect on chromatographic behavior and mass spectral response. Characterization typically employs high resolution MS to confirm mass shift, 1H and 2H NMR for labeling pattern verification, and LC with UV and MS detection to determine retention time and purity. Stability studies assess hydrogen-deuterium exchange under acidic or protic conditions. Manufacturing control strategies focus on limiting formation via optimized deuteration conditions, establishing qualification thresholds, and implementing routine batch-level assays. Defined acceptance criteria and traceability documentation ensure consistent impurity management.